Gerresheimer Reports Stable 2024 Financial Performance Amid Challenges

Gerresheimer AG announced solid financial results for 2024 despite facing market challenges. The company reported a revenue growth of 2.9% and an adjusted EBITDA increase of 4.1%. The adjusted EBITDA margin improved slightly to 20.6%. While the Primary Packaging Glass Division was impacted by destocking effects, the Plastics & Devices Division experienced significant growth, buoyed by demand for medical devices.

The acquisition of Bormioli Pharma is expected to positively impact Gerresheimer's revenues and adjusted EBITDA from 2025. The integration is progressing well, setting the stage for enhanced product offerings in high-value plastic solutions. Looking ahead, Gerresheimer anticipates organic revenue growth between 3-5% in 2025, with an improved EBITDA margin of around 22%.

The company remains optimistic about future growth, forecasting continued profitability driven by its strategies in biologics and expanded production capacities. Additionally, Gerresheimer has proposed maintaining a dividend of EUR 1.25 per share, reflecting steady financial performance and commitment to shareholder returns.